Table 3.
Primary and secondary efficacy outcomes in IMbrave 150 trial *.
| Results | Atezolizumab and Bevacizumab Combination | Sorafenib | Statistical Significance |
|---|---|---|---|
| Progression-free survival (months) | 6.9 (95% CI 5.7–8.6) | 4.3 (95% CI 4.0–5.6) | HR for disease progression: 0.65; 95% CI: 0.53–0.81; p < 0.001 |
| Overall survival (months) | 19.2 (95% CI: 17.0–23.7) | 13.4 months (95% CI 11.4–16.9) | Hazard ratio for death: 0.66; 95% CI: 0.52–0.85; p < 0.001 |
| Overall Response Rate (ORR) per RECIST 1.1 (%) | 29.8 (95% CI: 24.8–35.0) | 11.3 (95% CI: 6.9–17.3) | |
| CR based on RECIST 1.1 (%) | 8 | 0.6 | |
| Disease Control rate (ORR+ stable disease) (RECIST 1.1) (%) | 74 | 55 | |
| Median duration of response, months based on RECIST 1.1 | 18.1 (95% CI: 14.6-NE) | 14.9 (95% CI: 4.9–17.0) |
* After a median 15.6 (range, 0–28.6) months of follow-up.